Polygenic Embryo Screening: Towards Informed Decision-Making
多基因胚胎筛查:做出明智的决策
基本信息
- 批准号:10199368
- 负责人:
- 金额:$ 74.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AllelesAneuploidyAssisted Reproductive TechnologyAttitudeCellsComplex Genetic TraitConfidence IntervalsCoupledDataData SetDecision MakingDiabetes MellitusDiseaseEmbryoEndocrinologistEthical AnalysisEthicsFutureGeneral PopulationGenotypeHeart DiseasesHeightIndividualIndustryIntelligenceInterviewInvestigationKnowledgeMalignant NeoplasmsMendelian disorderMental disordersMethodologyModelingMotivationNoiseOutcomePartner in relationshipPatientsPhasePolygenic TraitsPreimplantation DiagnosisPrevalencePrivatizationPropertyPublishingReportingReproductive MedicineResearchResearch Project GrantsRiskRisk ReductionScreening procedureServicesShapesStigmatizationSurveysTechnologyTimeUncertaintyWorkbaseclinical applicationdesigndisorder riskethical legal social implicationevidence basegenetic counselorgenome-wideinterestnatural Blastocyst Implantationpleiotropismpolygenic risk scorepreferenceprenatalreproductivescreeningsimulationstakeholder perspectivestheoriestraitwillingness
项目摘要
PROJECT SUMMARY
Preimplantation genetic testing (PGT) has been utilized for years to avoid implantation of embryos
harboring rare monogenic disease-causing alleles or aneuploidies. However, recent progress in complex trait
genetics, coupled with the technical ability to generate accurate genome-wide genotypes from single-cell input,
has made it possible to genetically screen embryos for common polygenic traits and disease risk. While
popular media has raised the specter of ‘‘designer babies,’’ and private industry has begun to offer services of
dubious merit, little empirical work has been done to quantify the utility of polygenic embryo screening (PES),
examine its ethical implications, and assess stakeholders’ perspectives. Unlike conventional PGT, polygenic
risk scores are intrinsically probabilistic and multifaceted. The inherent ambiguities of PES requires careful
consideration in order for clinicians, policymakers, and the general public to make informed decisions about the
potential consequences of implementing polygenic embryo screening. Moreover, although research
momentum for polygenic risk scores has grown exponentially in the last few years, there is almost no
independent, empirical data on either: 1) the potential ability of PES to produce desired outcomes under
various real-world scenarios; or 2) the perspectives and attitudes of front-line clinicians in the potential clinical
application of polygenic risk scores, especially in the prenatal context.
In order to build an initial framework for the consideration of the ethical, legal, and social implications
(ELSI) of PES, it is necessary to establish two sets of empirical parameters: first, the statistical properties that
will shape the potential application of polygenic risk scores in the prenatal setting; and second, the attitudes
and perspectives of clinicians who would be at the front lines of administering PES, including genetic
counselors, reproductive endocrinologists, and obstetricians. The proposed study therefore aims to quantify
the range of realistic outcomes of PES in the context of disease risk reduction under varying conditions, using
a combination of simulated and real data. We also aim to understand the perspectives of clinicians who would
potentially deliver PES, using both in-depth interviews and a large-scale survey of reproductive clinicians and
geneticists. In the proposed research project, these two aims will be interdigitated and mutually informative;
statistical investigation will be guided by concerns and questions posed by stakeholders, and stakeholder
interviews and surveys will be shaped by the statistical and methodological understanding obtained from our
analyses. On the basis of our results, we will perform ethical analysis of this rapidly evolving technology.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHAI CARMI其他文献
SHAI CARMI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHAI CARMI', 18)}}的其他基金
Polygenic Embryo Screening: Towards Informed Decision-Making
多基因胚胎筛查:做出明智的决策
- 批准号:
10613568 - 财政年份:2021
- 资助金额:
$ 74.94万 - 项目类别:
Polygenic Embryo Screening: Towards Informed Decision-Making
多基因胚胎筛查:做出明智的决策
- 批准号:
10414053 - 财政年份:2021
- 资助金额:
$ 74.94万 - 项目类别:
相似海外基金
Elucidating the effects of extra chromosome elimination in mosaic aneuploidy syndromes: Pallister-Killian syndrome as a model
阐明额外染色体消除对嵌合非整倍体综合征的影响:以 Pallister-Killian 综合征为模型
- 批准号:
10887038 - 财政年份:2023
- 资助金额:
$ 74.94万 - 项目类别:
Characterization of aneuploidy, cell fate and mosaicism in early development
早期发育中非整倍性、细胞命运和嵌合体的表征
- 批准号:
10877239 - 财政年份:2023
- 资助金额:
$ 74.94万 - 项目类别:
The impact of aneuploidy on early human development
非整倍体对人类早期发育的影响
- 批准号:
MR/X007979/1 - 财政年份:2023
- 资助金额:
$ 74.94万 - 项目类别:
Research Grant
Understanding how aneuploidy disrupts quiescence in the model eukaryote Saccharomyces cerevisiae
了解非整倍体如何破坏模型真核生物酿酒酵母的静止状态
- 批准号:
10735074 - 财政年份:2023
- 资助金额:
$ 74.94万 - 项目类别:
Preventing Age-Associated Oocyte Aneuploidy: Mechanisms Behind the Drosophila melanogaster Centromere Effect
预防与年龄相关的卵母细胞非整倍性:果蝇着丝粒效应背后的机制
- 批准号:
10538074 - 财政年份:2022
- 资助金额:
$ 74.94万 - 项目类别:
Functional evaluation of kinesin gene variants associated with female subfertility and egg aneuploidy.
与女性生育力低下和卵子非整倍性相关的驱动蛋白基因变异的功能评估。
- 批准号:
10537275 - 财政年份:2022
- 资助金额:
$ 74.94万 - 项目类别:
Using CRISPR screening to uncover aneuploidy-specific genetic dependencies
使用 CRISPR 筛选揭示非整倍体特异性遗传依赖性
- 批准号:
10661533 - 财政年份:2022
- 资助金额:
$ 74.94万 - 项目类别:
Comparative Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos
哺乳动物胚胎非整倍性和细胞破碎动力学的比较分析
- 批准号:
10366610 - 财政年份:2022
- 资助金额:
$ 74.94万 - 项目类别:
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
FASEB SRC:非整倍体的后果:纪念 Angelika Amon 的贡献
- 批准号:
10467260 - 财政年份:2022
- 资助金额:
$ 74.94万 - 项目类别: